pharmacor metformin xr 500 metformin hydrochloride 500 mg extended release tablet bottle pack
pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; hypromellose; microcrystalline cellulose; copovidone; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
pharmacor metformin xr 750 metformin hydrochloride 750 mg extended release tablet blister pack
pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: carmellose sodium; magnesium stearate; microcrystalline cellulose; copovidone; hypromellose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
diaxemet xr 1000 metformin hydrochloride 1000 mg extended release tablet blister pack
pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; povidone; hypromellose; carmellose sodium; copovidone; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
diaxemet xr 750 metformin hydrochloride 750 mg extended release tablet bottle pack
pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; copovidone; carmellose sodium; hypromellose; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
diaxemet xr 1000 metformin hydrochloride 1000 mg extended release tablet bottle pack
pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; copovidone; magnesium stearate; carmellose sodium; povidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
pharmacor metformin xr 1000 metformin hydrochloride 1000 mg extended release tablet blister pack
pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; carmellose sodium; magnesium stearate; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
diaxemet xr 500 metformin hydrochloride 500 mg extended release tablet blister pack
pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; hypromellose; microcrystalline cellulose; magnesium stearate; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
pharmacor metformin xr 1000 metformin hydrochloride 1000 mg extended release tablet bottle pack
pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: hypromellose; copovidone; povidone; magnesium stearate; carmellose sodium; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin
coumadin warfarin sodium 2mg tablet bottle
viatris pty ltd - warfarin sodium, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose; magnesium stearate; maize starch; stearic acid; amaranth aluminium lake; indigo carmine aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.
coumadin warfarin sodium 5mg tablet bottle
viatris pty ltd - warfarin sodium, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; stearic acid; lactose; magnesium stearate; quinoline yellow aluminium lake; brilliant blue fcf aluminium lake - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism. coumadin is indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation. coumadin is not indicated in patients with lone atrial fibrillation who are less than 60 years of age with no risk factors (eg previous thromboembolism (tia, ischaemic stroke), diabetes mellitus, hypertension) and an otherwise normal heart. coumadin is indicated for use as an adjunct in the treatment of coronary occlusion.